| This perspective discusses the rapid evolution of anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. |
| Two of these treatments have been approved recently—the first new therapies for Alzheimer's disease to be approved in nearly 20 years and the first disease-modifying therapies to be approved for Alzheimer's disease. |
| Introduction of these unprecedented agents requires education of clinicians, patients, and care partners; adjustments in healthcare systems; and identification of reimbursement mechanisms |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.